Press releases

Advanced Search
  • Jul 24, 2014

    Boston Scientific Corporation (NYSE: BSX) generated sales of $1.873 billion during the second quarter ended June 30, 2014, compared to the company's guidance range for the quarter of $1.840 to...

  • Jul 23, 2014
    Innovative Technology Adds To Company's Leading Portfolio of Treatment Options for Coronary Artery Disease

    Continuing to advance the development of innovative treatment options for coronary artery disease, Boston Scientific Corporation (NYSE: BSX) has received CE Mark and begun the European market...

  • Jul 22, 2014
    Easy to Use Imaging System to Support Planned Intravascular Ultrasound and Fractional Flow Reserve Products

    Boston Scientific Corporation (NYSE: BSX) has initiated full commercial launch of the new POLARIS™ Imaging System. This system will support the Boston Scientific family of intravascular...

  • Jul 21, 2014
    Advanced Bare-Metal Stent Provides Additional Treatment Option for Interventional Cardiologists and Patients

    Boston Scientific Corporation (NYSE: BSX) has received FDA approval for the REBEL™ Platinum Chromium Coronary Stent System, the company's latest generation bare-metal stent for the treatment of...

  • Jul 14, 2014
    European Launch Means Physicians Can Now Choose From Three Available Valve Sizes To Match Patient Anatomy More Precisely

    Boston Scientific Corporation (NYSE: BSX) has received CE Mark and begun the European commercial launch of its new 25 mm Lotus™ Transcatheter Aortic Valve Implantation (TAVI) System,...

Show 5102550100 per page
Top